Introduction
============

Osteosarcoma, the most common malignant bone tumor, is a very devastating neoplasm, with an estimated annual incidence of 3--4 per million people.[@b1-ott-11-3495] Osteosarcoma frequently occurs in children and adolescents, accounting for \~20% of all primary sarcomas in bone tumor.[@b2-ott-11-3495] The precise mechanism underlying the developing osteosarcoma remains elusive; nonetheless, genetic factors are proposed to be involved in the progression of this cancer.[@b3-ott-11-3495] Currently, the standard treatment for osteosarcoma includes neoadjuvant therapy prior to definitive resection with wide margin, followed by multiple postoperative chemotherapeutic agents.[@b4-ott-11-3495] Cisplatin, a platinum analog that can inhibit cell division and growth through interfering with DNA, is one of the favorable agents for the effective combined chemotherapy in osteosarcoma treatment.[@b5-ott-11-3495],[@b6-ott-11-3495] However, over 40% of patients develop a poor response to cisplatin-based chemotherapy.[@b7-ott-11-3495] In addition, the prognosis for overall long-term survival in these patients remains unsatisfactory, with the overall 5-year event-free survival (EFS) of only 65%.[@b8-ott-11-3495] It is noteworthy that pharma-cogenomics has been perceived as a tool for personalized medicine, which can predict the response to chemotherapy as well as clinical outcome of cancer patients.[@b9-ott-11-3495] Consequently, comprehensive understanding of the role of pharmacogenetics contributes to selecting individualized chemotherapy for patients to improve their survival. Several recent studies have reported that gene polymorphisms, which are included in the excision repair cross complementation group (*ERCC*), may influence the prognosis for patients with osteosarcoma.

DNA damage is frequently induced by exogenous carcinogens, including ionizing radiation and ultraviolet rays, which can lead to genomic instability.[@b10-ott-11-3495] DNA repair, playing a critical role in maintaining genetic stability, is composed of several DNA repair pathways that can enable tumor cells to survive the chemotherapy-induced DNA damage.[@b11-ott-11-3495] Among all these pathways, the nucleotide excision repair (NER) is the most significant mechanism during the DNA repair process, which can recognize DNA damage and remove the damaged nucleotides.[@b12-ott-11-3495] As shown in previous studies, genetic variants in the DNA repair pathways may impair the DNA repair capacity and affect the prognosis for tumor patients.[@b13-ott-11-3495]--[@b15-ott-11-3495]

Considered as a significant factor of the DNA repair capacity, *ERCC* is the key element in the NER pathway. In addition, the *ERCC* genes are of crucial importance for genetic stability, and genetic alterations are predictive of the survival for tumor patients.[@b16-ott-11-3495]--[@b18-ott-11-3495] Notably, many recent studies have focused on the correlation of polymorphisms in *ERCC1* gene (rs11615, rs2298881, and rs3212986), *ERCC2* gene (rs13181 and rs1799793), *ERCC4* gene (rs1800067), or *ERCC5* gene (rs2296147 and rs1047768) with the prognosis for patients with osteosarcoma. However, the results are inconclusive and conflicting, which can be probably attributed to studies with a small sample size or ethnic differences. Herein, an updated meta-analysis of the published studies was conducted so as to comprehensively evaluate the association of *ERCC* polymorphisms with the clinical outcome in patients with osteosarcoma, hoping to provide helpful evidence and suggestions for future investigation.

Materials and methods
=====================

Search strategy
---------------

Studies dealing with prognostic implication of *ERCC* polymorphisms in patients with osteosarcoma were focused on in this meta-analysis. A comprehensive literature search was conducted in PubMed, Embase, and Web of Science up to July 2017. The following terms were used to search for relevant investigations in the abovementioned databases: "osteosarcoma or bone tumor" and "polymorphism or polymorphisms or variant or mutation" and "*ERCC*\* or *XPB* or *XPD* or *XPF* or *XPG*", in combination with "outcome or prognosis or survival". There was no restriction on population, language, time period, or type of study. References from retrieved articles and previous meta-analysis were examined to avoid any omission of eligible studies.

Inclusion and exclusion
-----------------------

We selected related eligible studies according to the strict inclusion criteria as follows: Case--control studies (for humans only);Detecting the association between *ERCC* variants and osteosarcoma prognosis or survival;Studies had to provide the information to estimate hazard ratios (HRs) and 95% CIs for prognostic effect of osteosarcoma;The study with the largest sample size or most recent publication date from all studies with overlapping data published by the same investigators was chosen.

Our exclusion criteria were as follows: Studies with overlapping or incomplete data;Literature types such as communications, letters, and reviews.

Data extraction
---------------

The following data from each eligible study were collected independently by two investigators: first author's name, year of publication, ethnicity of patients, sample size, chemotherapy drugs, clinical outcomes, and genotype distribution in cases and controls. In addition, HRs for overall survival (OS) and EFS, and their 95% CIs were extracted for statistical analysis. The corresponding author was contacted for detailed data by email. Disagreements were resolved by discussion with the third investigator.

Quality assessment
------------------

The quality of each study was assessed with the Newcastle-Ottawa Scale (NOS) for nonrandomized studies, independently by two investigators. The NOS consists of three parameters: case and control selection, comparability, and exposure. Studies with NOS scores \>6 were classified as high quality.[@b19-ott-11-3495]

Statistical analysis
--------------------

To estimate the relationship between *ERCC* polymorphisms and the survival in osteosarcoma patients, summary Cox proportional HRs with corresponding 95% CIs were utilized to evaluate EFS and OS by published methods.[@b20-ott-11-3495] Between-study statistical heterogeneity was assessed using the *χ*^2^ test-based Q statistic and the inconsistency index *I*^2^.[@b21-ott-11-3495] According to the Cochrane review guidelines, a fixed-effects model was used in the absence of heterogeneity (*P* \> 0.05 or *I*^2^ \< 50%), while a random-effects model was applied in existence of severe heterogeneity (*P* \< 0.05 or *I*^2^ \> 50%). The potential publication bias was tested by Begg's funnel plot and Egger's linear regression test; *P* \< 0.05 was deemed as a significantly selective bias.[@b22-ott-11-3495] STATA software (version 12.0; Stata-Corp, College Station, TX, USA) was utilized to deal with all meta-analyses.

Results
=======

Eligible studies
----------------

According to our search strategy we retrieved 24 studies from PubMed, 26 from Embase, and 22 from the Web of Science. Then 45 duplicated articles were removed, leaving 27 studies for further evaluation. The full text of the remainder of the studies was estimated for eligibility in accordance with our inclusion and exclusion criteria. Fourteen articles were excluded: five articles were about other tumors, two articles were reviews, two articles were letters, and eligible data for the meta-analysis were absent in five articles. Finally, a total of 13 studies including 2,303 patients were identified to be eligible for this meta-analysis.[@b23-ott-11-3495]--[@b35-ott-11-3495] The flowchart of literature selection process and reasons for exclusion are shown in [Figure 1](#f1-ott-11-3495){ref-type="fig"}.

Clinical characteristics of studies
-----------------------------------

The main clinical characteristics of all eligible studies associated with the prognosis of osteosarcoma are summarized in [Table 1](#t1-ott-11-3495){ref-type="table"}. Among these 13 enrolled studies, two studies were performed in Caucasian populations, while the remainder were based on Asian populations. All studies enrolled patients treated with chemotherapy. Of those, 12 articles focus on the relationship with OS, and three on relationship with EFS. This meta-analysis assessed the variant effect using a homozygous model.

*ERCC* polymorphisms and OS
---------------------------

### *ERCC*1 polymorphisms

Eight studies including 1,562 patients were incorporated to evaluate the association of OS with the *ERCC1* polymorphisms in rs11615, rs2298881, and rs3212986. In total, no statistically significant association was found (rs11615: HR = 1.23, 95% CI = 0.65--2.32, *P*~heterogeneity~ = 0.002, *I*^2^ = 68.3%; rs2298881: HR = 0.77, 95% CI = 0.11--5.39, *P*~heterogeneity~ = 0.012, *I*^2^ = 84.2%; rs3212986: HR = 0.90, 95% CI = 0.54--1.50, *P*~heterogeneity~ = 0.420, *I*^2^ = 0.0%). Furthermore, results from stratified analysis by ethnicity indicated that rs11615 and rs3212986 may have no association with OS in both Asians and Caucasians ([Table 2](#t2-ott-11-3495){ref-type="table"}).

### *ERCC2* polymorphisms

Nine eligible studies consisting of 1,677 patients were included in this evaluation. The rs13181 polymorphism was not significantly associated with OS (HR = 1.07, 95% CI = 0.70--1.65, *P*~heterogeneity~ = 0.376, *I*^2^ = 7.1%). Stratified analysis by ethnicity also showed no correlation in both Asians and Caucasians ([Table 2](#t2-ott-11-3495){ref-type="table"}). However, positive results were found between rs1799793 and OS (TT vs GG: HR = 0.62, 95% CI = 0.41--0.93, *P*~heterogeneity~ = 0.310, *I*^2^ = 15.3%, *P* = 0.020), which indicated that patients with TT genotype showed a better survival as compared to GG ([Figure 2](#f2-ott-11-3495){ref-type="fig"}). Stratified analysis showed that the significance remained in Asians, but not in Caucasians (Asians: HR = 0.63, 95% CI = 0.41--0.96, *P*~heterogeneity~ = 0.228, *I*^2^ = 26.3%; Caucasians: HR = 0.48; 95% CI = 0.11--2.05) ([Table 2](#t2-ott-11-3495){ref-type="table"}).

### *ERCC4* polymorphisms

Two studies with 318 Asian patients were included in this meta-analysis. There was no evidence to support an association between the *ERCC4* rs1800067 polymorphism and OS (HR = 0.56, 95% CI = 0.13--2.39, *P*~heterogeneity~ = 0.510, *I*^2^ = 0.0%; [Table 2](#t2-ott-11-3495){ref-type="table"}).

### *ERCC5* polymorphisms

Four studies including 707 Asian patients with osteosarcoma were included in the final analysis to reveal the association of OS with the *ERCC5* polymorphisms in rs1047768 and rs2296147 ([Table 2](#t2-ott-11-3495){ref-type="table"}). The pooled outcome indicated that the rs1047768 polymorphism was not associated with OS in all patients (HR = 0.55, 95% CI = 0.23--1.29, *P*~heterogeneity~ = 0.335, *I*^2^ = 0.0%). Nevertheless, pooling of data from the rs2296147 polymorphism showed a trend toward an increase in survival of disease with HR of 0.42 (TT vs CC: 95% CI = 0.23--0.78, *P*~heterogeneity~ = 0.708, *I*^2^ = 0.0%, *P* = 0.006; [Figure 3](#f3-ott-11-3495){ref-type="fig"}). The result indicated that patients with rs2296147 TT genotype showed a better survival as compared to CC.

*ERCC* polymorphisms and EFS
----------------------------

### *ERCC1* polymorphisms

Three studies with 488 patients investigating possible associations between the *ERCC1* rs11615 polymorphism and EFS were included in the final analysis, one of which included Asians. Overall, there was no statistically significant association in all patients (HR = 0.61, 95% CI = 0.37--1.02, *P*~heterogeneity~ = 0.280, *I*^2^ = 21.4%). Nevertheless, subgroup analysis by ethnicity showed a positive result in Asian patients (HR = 0.39, 95% CI = 0.14--0.95). These studies also investigated the relationship of the *ERCC1* rs3212986 polymorphism and EFS, two of which included Caucasians. In total, no significant correlation was found (HR = 1.04, 95% CI = 0.61--1.75, *P*~heterogeneity~ = 0.149, *I*^2^ = 47.5%). The ethnic subgroup analysis also demonstrated no association in Asians or Caucasians (Asians: HR = 0.65, 95% CI = 0.43--1.76; Caucasians: HR = 1.86, 95% CI = 0.84--4.09, *P*~heterogeneity~ = 0.872, *I*^2^ = 0.0%). The results can be found in [Table 3](#t3-ott-11-3495){ref-type="table"}.

### *ERCC2* polymorphisms

Three eligible studies of 488 patients were included in the final analysis to investigate the correlation of the *ERCC2* rs13181 polymorphism and EFS. Overall, negative results were found in all patients (HR = 1.97, 95% CI = 0.49--8.03, *P*~heterogeneity~ = 0.025, *I*^2^ = 72.9%). In the subgroup analysis by ethnicity, the results were not significant in Asians or Caucasians (Asians: HR = 2.27, 95% CI = 0.77--6.70; Caucasians: HR = 2.01, 95% CI = 0.15--27.70, *P*~heterogeneity~ = 0.010, *I*^2^ = 85.1%). These studies were also eligible for the final analysis of association between the *ERCC2* rs1799793 polymorphism and EFS. Pooling of data did not show positive results (HR = 0.91, 95% CI = 0.23--3.65, *P*~heterogeneity~ = 0.025, *I*^2^ = 72.9%). Furthermore, stratified analysis showed negative results in Asian and Caucasian populations (Asians: HR = 0.82, 95% CI = 0.30--1.85; Caucasians: HR = 0.95, 95% CI = 0.06--14.97, *P*~heterogeneity~ = 0.007, *I*^2^ = 86.3%). [Table 3](#t3-ott-11-3495){ref-type="table"} gives a summary of the results.

Publication bias
----------------

Publication bias was assessed in the evaluation of the relationship between *ERCC* polymorphisms and survival of osteosarcoma by the homozygous model. The shapes of funnel plots showed no evidence of obvious asymmetry ([Figure 4](#f4-ott-11-3495){ref-type="fig"}). Moreover, the results of Begg's and Egger's test confirmed this finding (*ERCC1* rs11615: *P*~Begg~ = 0.71, *P*~Egger~ = 0.78; *ERCC2* rs13181: *P*~Begg~ = 0.12, *P*~Egger~ = 0.06; *ERCC2* rs1799793: *P*~Begg~ = 0.39, *P*~Egger~ = 0.46). For the other *ERCC* polymorphisms, we did not assess publication bias due to the comparatively smaller number of articles used in the analysis.

Discussion
==========

DNA repair, which is critical to maintain genetic stability, used at least four major pathways, including base excision repair, mismatch repair, NER, and double-strand break repair.[@b36-ott-11-3495] Among them, NER is the major pathway used by mammals to remove the bulky DNA lesions, which may also prevent the accumulation of DNA damage-induced mutation in humans.[@b37-ott-11-3495] *ERCC1*, *ERCC2*, *ERCC4*, and *ERCC5* are the important factors involved in NER, based on recent studies. During NER, *ERCC1* is located at 19q13.2 and can repair the chemical drug-induced DNA damage.[@b38-ott-11-3495] Moreover, the *ERCC1*--xenopsin precursor fragment (*XPF*) complex is a highly conserved endonuclease, which plays a critical role in a variety of other key repair pathways. In addition, McNeil et al[@b39-ott-11-3495] revealed that *ERCC1--XPF* might be a novel therapeutic target to overcome chemoresistance in cancer therapy. *ERCC2*, which maps at 19q13.3, is composed of 23 exons and spans about 54 kb. Furthermore, mutations in *ERCC2* gene can lead to defective DNA repair. Chu et al[@b40-ott-11-3495] observed that the *ERCC2* rs13181 TG/GG could prolong the survival time in the Chinese population with gastric cancer. *ERCC4*, located on chromosome 16p13.12, is composed of 11 exons and spans \~28.2 kb. Moreover, *ERCC4* has previously demonstrated to be a human gene correcting the NER deficiency in somatic cell hybrids of mutant hamster cells. In addition, Vaezi et al[@b41-ott-11-3495] investigated the association of the *ERCC4* expression level with the clinical response to DNA damaging agents in head and neck squamous cell carcinoma. Their results identified four *ERCC4* single-nucleotide polymorphisms, which revealed a marginal association with treatment failure. Additionally, *ERCC5*, the central component of NER, participates in the 5′ incision mediated by the *ERCC1* and *ERCC4* heterodimer. Moreover, Zhao et al[@b35-ott-11-3495] reported that the *ERCC5* mRNA expression level was related to the cytotoxicity of cisplatin; meanwhile, the *ERCC5* polymorphisms were correlated with the response to chemotherapy and prognosis of osteosarcoma. Particularly, in recent studies the efficiency of DNA damage repair systems has been shown to be of critical importance and can result in the individual differences in clinical prognosis for osteosarcoma patients treated with chemotherapy.[@b31-ott-11-3495],[@b42-ott-11-3495] Furthermore, many clinical studies published within the past several years have extensively investigated the association of *ERCC* genetic polymorphisms with the prognosis for osteosarcoma patients. However, no consistent results can be obtained from these studies.

Meta-analysis is a statistical analysis that combines a larger sample size than with any individual studies so the results are more precise and robust than any single study. Therefore, we conducted a meta-analysis to elucidate the association between *ERCC* polymorphisms and the prognosis for osteosarcoma patients from all relevant published studies. OS and EFS, which are intrinsically correlated but not necessarily consistent with each other, were used as the primary parameters after the extracted data were analyzed. Additionally, Li et al[@b43-ott-11-3495] demonstrated significant correlation between the polymorphisms in *ERCC2* rs13181 and the OS in patients with osteosarcoma through assessing the homozygous models. Notably, our updated analysis with more data exactly indicated that the polymorphisms in *ERCC2* rs13181 were not necessarily associated with the OS in all patients (HR = 1.17, 95% CI = 0.74--1.83, *P*~heterogeneity~ = 0.438, *I*^2^ = 0.0%). In our study, an obvious association was found in *ERCC2* rs1799793 and *ERCC5* rs2296147 polymorphisms with the OS in osteosarcoma patients, indicating that these polymorphisms may be the important prognostic factors of osteosarcoma, especially in Asian populations. However, no significant association was observed between *ERCC2* rs1799793 and EFS upon analysis of only three eligible studies. To date, no data are available to assess the relationship between *ERCC5* rs2296147 and EFS. Therefore, more future studies are required to confirm the possible prognostic role of rs1799793 and rs2296147 polymorphisms in osteosarcoma. Taking into account the extracted EFS data from some of the studies, we found that genetic polymorphisms in *ERCC1* and *ERCC2* were not associated with EFS in all patients. However, positive results can be observed in further stratified analyses by ethnicity, in which only one study involving 267 Asian patients examined the relationship between *ERCC1* rs11615 and EFS (HR = 0.39, 95% CI = 0.14--0.95). Therefore, further studies regarding the prognosis for osteosarcoma should be performed to draw more reliable results in the future.

We performed a comprehensive meta-analysis to identify the possible association of *ERCC* polymorphisms with the clinical outcome of osteosarcoma. However, several limitations should be taken into consideration when interpreting our results. First, a relatively small number of studies, as we mentioned above, were included in this meta-analysis. Secondly, studies involving only Asians and Caucasians were included for analysis. Accordingly, future studies enrolling other ethnicities should be carried out to investigate the possibility of a race-specific association. What is more, unpublished relevant articles were excluded from the current meta-analysis. In addition, all Asian studies were performed in the People's Republic of China. Pan et al[@b44-ott-11-3495] conducted a study on the interaction of selective reporting and language biases in human genome epidemiology by targeting gene--disease associations. Their findings indicated that a critical and comprehensive global view was needed for human genome epidemiology. Besides, failure to maintain a global outlook may result in bias in medical-scientific literature. Consequently, it is necessary to study more non-Chinese studies of Asian-descent populations, so as to confirm the obvious association in Asians.

Despite the shortages mentioned above, there are many advantages in our meta-analysis. First of all, to our knowledge, the most comprehensive and updated assessment of this association was presented in the current meta-analysis, with the inclusion of new studies. Secondly, the literature retrieval strategy, which includes manual and computer-assisted retrieval, was rigorous enough to identify all the relevant studies with the most comprehensive data possible at the time. Thirdly, data extraction and analysis criteria of the selected literature were designed rationally. Finally, no publication bias was observed in the models of the polymorphisms in rs11615, rs13181, and rs1799793. Consequently, we drew a stable and reliable conclusion. Previous reports of clinical research show that despite tremendous advances in chemotherapy options and surgical procedures, osteosarcoma generally has a poor prognosis, especially in patients with recurrent disease or metastases. Therefore, it is of significant importance to support more research efforts on basic research and clinical translation about osteosarcoma, so as to meet clinical need.

Conclusion
==========

With a pooled dataset of 2,303 patients treated with chemotherapy, we made a comprehensive assessment of prognosis for osteosarcoma by OS and EFS. We observed that the TT genotype in the *ERCC2* rs1799793 and *ERCC5* rs2296147 can prolong the survival time, suggesting that the rs1799793 and rs2296147 polymorphisms can be used as predictors for prognosis of osteosarcoma patients treated with chemotherapy, especially in Asian populations. Further high-quality and multicenter studies should be conducted to confirm our findings.
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![Flowchart of the selection procedure of the studies and reasons for exclusion.\
**Abbreviation:** *ERCC*, excision repair cross complementation.](ott-11-3495Fig1){#f1-ott-11-3495}

![Forest plots of overall survival in osteosarcoma patients treated with chemotherapy by *ERCC2* rs1799793 polymorphism: TT vs GG.\
**Abbreviations:** *ERCC*, excision repair cross complementation; ES, effect size; ND, no data.](ott-11-3495Fig2){#f2-ott-11-3495}

![Forest plots of overall survival in osteosarcoma patients treated with chemotherapy by *ERCC5* rs2296147 polymorphism: TT vs CC.\
**Abbreviations:** *ERCC*, excision repair cross complementation; ES, effect size.](ott-11-3495Fig3){#f3-ott-11-3495}

![Begg's funnel plot of publication bias test for the association between overall survival in osteosarcoma patients treated with chemotherapy and three *ERCC* polymorphisms.\
**Notes:** (**A**) *ERCC1* rs11615: TT vs CC; (**B**) *ERCC2* rs13181: GG vs TT; (**C**) *ERCC2* rs1799793: TT vs GG.\
**Abbreviations:** *ERCC*, excision repair cross complementation; HR, hazard ratio; log\[HR\], natural logarithm of the HR; SE, standard error.](ott-11-3495Fig4){#f4-ott-11-3495}

###### 

Summary of characteristics for the eligible studies

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                             Year   Ethnicity   Case number   Male (%)   Polymorphisms                             Genotyping method   Assessment method   Treatment                                               M-FU (months)
  --------------------------------- ------ ----------- ------------- ---------- ----------------------------------------- ------------------- ------------------- ------------------------------------------------------- -------------------------------------------------
  Caronia et al[@b26-ott-11-3495]   2009   Caucasian   91            56.04      *ERCC1*: rs11615, rs3212986\              TaqMan              EFS                 Cisplatin-based chemotherapy                            91 (10--272)
                                                                                *ERCC2*: rs13181, rs1799793                                                                                                               

  Yang et al[@b33-ott-11-3495]      2012   Asian       187           56.68      *ERCC1*: rs11615\                         PCR-RFLP            OS                  Cisplatin-based chemotherapy before and after surgery   NA, patients from January 2005 to January 2007
                                                                                *ERCC2*: rs13181                                                                                                                          

  Hao et al[@b27-ott-11-3495]       2012   Asian       267           65.54      *ERCC1*: rs11615, rs3212986\              PCR                 OS, EFS             Cisplatin-based chemotherapy                            44.3
                                                                                *ERCC2*: rs1799793, rs13181                                                                                                               

  Bai et al[@b23-ott-11-3495]       2013   Asian       185           58.38      *ERCC5*: rs2296147                        PCR                 OS                  Cisplatin-based chemotherapy                            NA, patients from January 2007 to December 2009

  Sun et al[@b30-ott-11-3495]       2013   Asian       182           60.44      *ERCC5*: rs1047768                        PCR                 OS                  Cisplatin-based chemotherapy                            41.5

  Zhao et al[@b35-ott-11-3495]      2013   Asian       168           57.74      *ERCC5*: rs2296147                        PCR                 OS                  Cisplatin-based chemotherapy                            NA, patients from January 2007 to March 2009

  Biason et al[@b24-ott-11-3495]    2012   Caucasian   130           60.77      *ERCC1*: rs11615, rs3212986\              PCR                 OS, EFS             Cisplatin-based chemotherapy                            38 (1--278)
                                                                                *ERCC2*: rs13181, rs1799793                                                                                                               

  Wang et al[@b32-ott-11-3495]      2015   Asian       146           64.38      *ERCC1*: rs11615\                         PCR-RFLP            OS                  Chemotherapy                                            NA, patients from 2008 to 2013
                                                                                *ERCC2*: rs13181, rs1799793\                                                                                                              
                                                                                *ERCC4*: rs1800067                                                                                                                        

  Zhang et al[@b34-ott-11-3495]     2015   Asian       260           55.38      *ERCC1*: rs11615, rs3212986\              PCR-RFLP            OS                  Cisplatin-based chemotherapy                            NA, patients from 2010 to 2011
                                                                                *ERCC2*: rs13181, rs1799793                                                                                                               

  Ji et al[@b28-ott-11-3495]        2015   Asian       214           62.15      *ERCC1*: rs11615\                         PCR-RFLP            OS                  Cisplatin-based chemotherapy                            36.5 (4--60)
                                                                                *ERCC2*: rs1799793, rs13181                                                                                                               

  Sun et al[@b31-ott-11-3495]       2015   Asian       172           66.28      *ERCC1*: rs11615, rs2298881\              PCR-RFLP            OS                  Chemotherapy                                            NA, patients from 2009 to 2011
                                                                                *ERCC2*: rs1799793, rs13181\                                                                                                              
                                                                                *ERCC4*: rs1800067\                                                                                                                       
                                                                                *ERCC5*: rs1047768                                                                                                                        

  Liu et al[@b29-ott-11-3495]       2015   Asian       115           56.52      *ERCC2*: rs1799793, rs13181               PCR                 OS                  Cisplatin-based chemotherapy                            NA

  Cao et al[@b25-ott-11-3495]       2015   Asian       186           57.53      *ERCC1*: rs11615, rs2298881, rs3212986\   PCR-RFLP            OS                  Cisplatin-based chemotherapy                            38.5 (3--60)
                                                                                *ERCC2*: rs1799793, rs13181                                                                                                               
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** EFS, event-free survival; *ERCC*, excision repair cross complementation; M-FU, median follow-up; NA, not available; OS, overall survival; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism.

###### 

Meta-analysis of *ERCC* polymorphisms with overall survival in osteosarcoma

  Allele/genotype                Number of studies   HR (95% CI)         Heterogeneity test   Model   
  ------------------- ---------- ------------------- ------------------- -------------------- ------- ----
  *ERCC1* rs11615                                                                                     
   All                TT vs CC   8                   1.23 (0.65--2.32)   0.002                68.3    R
   Asian              TT vs CC   7                   1.32 (0.64--2.73)   0.002                71.5    R
   Caucasian          TT vs CC   1                   0.76 (0.30--1.97)   NA                   NA      NA
  *ERCC1* rs2298881   AA vs CC   2                   0.77 (0.11--5.39)   0.012                84.3    R
  *ERCC1* rs3212986                                                                                   
   All                TT vs GG   4                   0.90 (0.54--1.50)   0.420                0.0     F
   Asian              TT vs GG   3                   0.69 (0.38--1.25)   0.979                0.0     F
   Caucasian          TT vs GG   1                   1.78 (0.69--4.58)   NA                   NA      NA
  *ERCC2* rs13181                                                                                     
   All                GG vs TT   9                   1.07 (0.70--1.65)   0.376                7.1     F
   Asian              GG vs TT   8                   1.17 (0.74--1.83)   0.438                0.0     F
   Caucasian          GG vs TT   1                   0.41 (0.09--1.83)   NA                   NA      NA
  *ERCC2* rs1799793                                                                                   
   All                TT vs GG   8                   0.62 (0.41--0.93)   0.310                15.3    F
   Asian              TT vs GG   7                   0.63 (0.41--0.96)   0.228                26.3    F
   Caucasian          TT vs GG   1                   0.48 (0.11--2.05)   NA                   NA      NA
  *ERCC4* rs1800067   AA vs GG   2                   0.56 (0.13--2.39)   0.510                0.0     F
  *ERCC5* rs2296147   TT vs CC   2                   0.42 (0.23--0.78)   0.708                0.0     F
  *ERCC5* rs1047768   TT vs CC   2                   0.55 (0.23--1.29)   0.335                0.0     F

**Abbreviations:** *ERCC*, excision repair cross complementation; F, fixed-effects model; HR, hazard ratio; NA, not available; R, random-effects model.

###### 

Meta-analysis of *ERCC* polymorphisms with event-free survival in osteosarcoma

  Allele/genotype                Number of studies   HR (95% CI)          Heterogeneity test   Model   
  ------------------- ---------- ------------------- -------------------- -------------------- ------- ----
  *ERCC1* rs11615                                                                                      
   All                TT vs CC   3                   0.61 (0.37--1.02)    0.280                21.4    F
   Asian              TT vs CC   1                   0.39 (0.14--0.95)    NA                   NA      NA
   Caucasian          TT vs CC   2                   0.73 (0.40--1.35)    0.245                25.9    F
  *ERCC1* rs3212986                                                                                    
   All                TT vs GG   3                   1.04 (0.61--1.75)    0.149                47.5    F
   Asian              TT vs GG   1                   0.65 (0.43--1.76)    NA                   NA      NA
   Caucasian          TT vs GG   2                   1.86 (0.84--4.09)    0.872                0.0     F
  *ERCC2* rs13181                                                                                      
   All                GG vs TT   3                   1.97 (0.49--8.03)    0.025                72.9    R
   Asian              GG vs TT   1                   2.27 (0.77--6.70)    NA                   NA      NA
   Caucasian          GG vs TT   2                   2.01 (0.15--27.70)   0.010                85.1    R
  *ERCC2* rs1799793                                                                                    
   All                TT vs GG   3                   0.91 (0.23--3.65)    0.025                72.9    R
   Asian              TT vs GG   1                   0.82 (0.30--1.85)    NA                   NA      NA
   Caucasian          TT vs GG   2                   0.95 (0.06--14.97)   0.007                86.3    R

**Abbreviations:** *ERCC*, excision repair cross complementation; F, fixed-effects model; HR, hazard ratio; NA, not available; R, random-effects model.

[^1]: These authors contributed equally to this work
